Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $14,182 | $28,866 | $1,262 | $26,554 |
| % Growth | -50.9% | 2,187.3% | -95.2% | – |
| Cost of Goods Sold | $10 | $209 | $30 | $25,933 |
| Gross Profit | $14,172 | $28,657 | $1,232 | $621 |
| % Margin | 99.9% | 99.3% | 97.6% | 2.3% |
| R&D Expenses | $18,757 | $15,571 | $15,303 | $26,685 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $7,602 | $9,350 | $11,608 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $6,673 |
| Operating Expenses | $26,359 | $24,921 | $26,911 | $33,358 |
| Operating Income | -$12,187 | $3,736 | -$25,679 | -$32,737 |
| % Margin | -85.9% | 12.9% | -2,034.8% | -123.3% |
| Other Income/Exp. Net | -$582 | -$484 | $384 | -$1,029 |
| Pre-Tax Income | -$12,769 | $3,252 | -$25,295 | -$33,766 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,769 | $3,252 | -$25,295 | -$33,766 |
| % Margin | -90% | 11.3% | -2,004.4% | -127.2% |
| EPS | -0.04 | 0.009 | -0.07 | -0.09 |
| % Growth | -544.4% | 112.9% | 22.2% | – |
| EPS Diluted | -0.04 | 0.009 | -0.07 | -0.09 |
| Weighted Avg Shares Out | 363,399 | 363,294 | 362,073 | 361,492 |
| Weighted Avg Shares Out Dil | 363,399 | 363,570 | 362,073 | 361,492 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1,834 | $2,219 | $2,829 |
| Interest Expense | $2,155 | $2,318 | $1,835 | $3,858 |
| Depreciation & Amortization | $151 | $176 | $176 | $125 |
| EBITDA | -$10,463 | $5,746 | -$23,284 | -$20,312 |
| % Margin | -73.8% | 19.9% | -1,845% | -76.5% |